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ma tism (EULAR) good clinical response, EULAR good/
/moderate response, 28-joint Disease Activity Score
with three variables including the erythrocyte sedi-
mentation rate (DAS28-3V-ESR) remission and Health
Assessment Questionnaire (HAQ) response were per-
formed. Multivariable logistic regression using a for-
ward selection procedure was used until the best-fit
model was obtained, taking confounding effects into
account. A total of 180 patients were eligible for the
study (mean age 52 years, 54% women). In multivaria -
ble analysis at 3 months, females were less likely to at-
tain a good EULAR response [OR=0.082 (95%
CI=0.024, 0.278)], a DAS28-3V-ESR remission
[OR=0.083 (95% CI=0.017, 0.416)], a moderate or
good EULAR response [OR=0.091 (95% CI=0.011,
0.091)] and a HAQ response [OR=0.074 (95%
CI=0.009, 0.608)]. At 6 months, female gender was
also less likely to achieve a good EULAR response
[OR=0.060 (95% CI=0.011, 0.325)], DAS28-3V-ESR
remission [OR=0.060 (95% CI=0.012, 0.297)], and a
HAQ response [OR=0.138 (95% CI= 0.029, 0.654)]. In
this study we found that gender was the most consis-
tent predictor of response to TNF blocker therapy in
patients with polyarticular PsA, with females having a
lower probability of response compared to males. These
findings suggest that gender-related biochemical, hor-
monal and psychological factors could play an impor-
tant role in the response to TNF blocker therapy in PsA.
Keywords: Treatment response; TNF blockers; Psoria -
tic arthritis;
IntroductIon
Psoriatic arthritis (PsA) is a chronic inflammatory
rheumatic disease characterized by the involvement of
peripheral and axial joints, entheses, skin and nails. Tu-
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AbstrAct 
Psoriatic arthritis (PsA) is a chronic inflammatory
rheumatic disease with a broad clinical spectrum. PsA
can affect the axial skeleton, peripheral joints, entheses,
synovial sheaths of tendons, skin, nails and extra-arti -
cular organs. Tumour necrosis factor alpha blockers
(TNF blockers) were a breakthrough development in
the treatment of PsA. Identifying predictors of response
to biological therapies in patients with PsA is of utmost
importance, especially in view of the costs and poten-
tial side effects of these agents. The aims of the present
study were to determine baseline predictive factors of
response to biological therapies, at 3 and 6 months, in
PsA patients with polyarticular involvement (with or
without axial involvement). Data were collected from
the Rheumatic Diseases Portuguese Register (Reuma.pt).
Eligible patients had to be anti-TNF-naive at baseline
and to have at least 3 months of follow-up after the be-
ginning of TNF blocker therapy. Only patients with in-
formation on at least one of the response measures (at
3 or 6 months of follow-up) were included in the analy -
sis. Univariable logistic regression analysis of potential
baseline predictors of European League Against Rheu -
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mour necrosis factor (TNF) blockers (adalimumab,
etanercept, golimumab, infliximab and certolizumab)
were a breakthrough development in the treatment of
PsA. These agents have been found, in randomized
controlled clinical trials, to effectively improve sever-
al manifestations of the disease, including peripheral
arthritis, psoriasis, enthesitis and dactylitis, while also
preven ting radiographic damage1-7.
According to the Portuguese recommendations for
the use of biological therapies in patients with psoria -
tic arthritis8, patients should be considered candidates
to biological therapy when 5 or more swollen joints
(of 66 joint count) are present, on two separate occa-
sions, at least 1 month apart, after failure of conventio -
nal therapies. This is defined as an absence of response
to treatment with at least one conventional synthetic
disease modifying anti-rheumatic drug (csDMARD)
(methotrexate or leflunomide), for at least 3 months on
a standard (full) target dose, unless there is intoleran -
ce, toxicity or contraindication. In the absence of poor
prognostic factors, a second csDMARD (methotrexate,
sulfasalazine, leflunomide, cyclosporine) or an associa -
tion of csDMARDs can be considered, with reassess-
ment after 3 additional months of therapy.
The identification of predictors of response could
help clinicians to make evidence-based decisions to
maximize the benefits of treatment, by targeting sub-
sets of patients most likely to respond, at the early
stages of the decision process. This would also improve
the cost/benefit and benefit/risk ratios in patients se-
lected to start TNF blocker therapy.
Most studies that evaluated predictors of response
to TNF blockers are based on national registries of
rheumatic patients. These studies suggested several
predictive factors of a better response, including
younger age, male gender, number of swollen joints,
elevated C-reactive protein (CRP) levels and no use of
corticosteroids. Of interest, no significant difference in
efficacy has been found between the different anti-TNF
therapies9. Despite these contributions, predicting res -
ponse to treatment to biologic DMARDs (bDMARDs)
and to other DMARDs is still an important subject of
debate and research as highlighted in the recently pu -
blished European League Against Rheumatism (EU-
LAR) recommendations for the management of PsA10.
The aim of the present study was to determine
baseli ne predictive factors of response to biological
therapies, at 3 and 6 months, in PsA patients with po -
lyar ticular involvement (with or without axial invol ve -
ment).
Methods
PoPulAtIon
Data were collected from the Rheumatic Diseases Por-
tuguese Register (Reuma.pt), which is a nation-wide
prospective longitudinal cohort, initiated in 200611,12.
The Portuguese Data Protection Authority and local
ethics committees approved this registry and patients
gave formal written informed consent to participate in
Reuma.pt.
We included all registered patients with the diag-
nosis of PsA, according to the treating rheumatologist,
starting the first TNF blocker agent, and with at least
3 months of follow-up. Patients with oligoarticular or
mutilans forms of PsA were excluded. Only patients
with information on at least one of the response mea-
sures, both at baseline and at 3 or 6 months of follow-
-up, were included in the analyses.
resPonse MeAsures
The primary response outcome was a good EULAR
clinical response [improvement in 28-joint Disease
Acti vity Score (DAS28) from baseline >1.2 and DAS28
at endpoint ≤3.2]13. The validity of the DAS/DAS28 in
patients with polyarticular PsA has been consistently
shown14. The secondary response measures were: 
EULAR moderate/good response, DAS28 remission
(DAS28<2.6) and HAQ response [defined as the
achievement of a HAQ ≤0.5 and/or a decrease in the
HAQ ≥0.22 (proposed as being the minimal clinically
important difference in the HAQ score)]15. Regarding
the DAS28 definition, we used the definition with 3
variables including the erythrocyte sedimentation rate
(DAS28-3V-ESR).
dAtA collectIon
Information on sociodemographic data [age, gender,
educational level, current smoking status, current al-
cohol use, body mass index (BMI)] and clinical data
[disease duration since first symptoms, HLA-B27 sta-
tus, PsA subtype, rheumatoid factor (RF), antibodies
anti-cyclic citrullinated peptides (ACPA), presence of
extra-articular manifestations, tender and swollen
joints (28-count), erythrocyte sedimentation rate
(ESR), CRP, patient global assessment (PGA) Visual
Analogic Scale (VAS) treatment with methotrexate
(MTX), and the TNF blocker used (infliximab, adali-
mumab, etanercept or golimumab)] were collected at
baseline. In the data collected, there were no patients
receiving certolizumab as first TNF blocker. Data on
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physical function (HAQ) and DAS28-3V-ESR was col-
lected at 3 time points: 0, 3 and 6 months.
stAtIstIcAl AnAlysIs
Age, female gender, disease duration since diagnosis,
smoking status, alcohol use, educational level, BMI,
presence of extra-articular manifestations, baseline di -
sease activity measures (tender and swollen joints (28-
-joint count), ESR and CRP, DAS28-3V-ESR, PGA (VAS
scale), treatment with MTX and physical function
(HAQ) were analyzed as baseline predictors in univa -
riable logistic regression analysis, using EULAR good
clinical response, EULAR good/moderate response,
DAS28-3V-ESR remission and HAQ response at 3
months and at 6 months as the dependent variables.
Variables with a p-value <0.05 were re-tested in multi-
variable models. A manual forward selection procedure
was performed until the best-fit model was obtained,
taking confounding variables into account. Analyses
were performed with IBM SPSS Statistics (version 20.0).
results
PAtIent chArActerIstIcs
A total of 433 patients registered in Reuma.pt satisfied
the eligibility criteria: anti-TNF-naïve, polyarticular PsA
and at least 3 months of follow-up. However, after ex-
cluding patients without information on at least one of
the res ponse measures, at 3 or 6 months of follow-up, a
total of 180 patients were available for analysis. There
were no clinical or demographic differences between the
180 patients included in the analysis and the 253 pa-
tients excluded because of missing response criteria at
follow-up (data not shown), except in the number of
swollen joints (6.20±4.19 in the included dataset and
4.54±4.54 in the excluded dataset, p-value 0.03) and in
the prevalence of HLA-B27 (16.8% in the included
dataset and 22.2% in the excluded dataset, p-value
0.003).
The demographic characteristics of the study popu -
lation, baseline disease activity measures, TNF blo cker
used and response measures at 3 and 6 months, are
presented in Table I.
resPonse MeAsures
A good EULAR response was observed in 44.2% and
57.8% of the patients, at 3 months and 6 months, res -
pectively. DAS28-3V-ESR remission was achieved by
31.8% of patients, at 3 months and 49.2%, at 6
months. At 3 months, 83.7% of patients presented a
moderate or good EULAR response, which slightly in-
creased to 86.7%, at 6 months. HAQ response was
achieved 78.5% and 82.8% of patients, at 3 and 6
months, respectively (Table I).
unIvArIAble AnAlysIs
At 3 months, a good EULAR response was more proba -
ble in males and in patients with longer disease dura-
tion, at the start of the first biologic agent (Table II).
DAS28-3V-ESR remission was associated with gender,
swollen and tender joints counts, PGA, ESR, DAS28-
-3V-ESR and HAQ, at baseline (Table III). Mode ra -
te/good EULAR response was associated with gender,
BMI and HAQ score at baseline (Table IV). The HAQ
response was associated with female gender (Table V).
At 6 months, a good EULAR response was associa -
ted with current alcohol use and inversely associated
with female gender, BMI, tender joints count and PGA
(Table II). DAS28-3V-ESR remission was negatively as-
sociated with female gender, age, swollen and tender
joints counts, CRP, ESR, DAS28-3V-ESR and HAQ at
baseline (Table III). Moderate/good EULAR response
was associated with MTX use and swollen joint count
(Table IV). The HAQ response was associated with fe-
male gender (Table V).
MultIvArIAble AnAlysIs
In multivariable analysis at 3 months, females were less
likely to attain a good EULAR response and this res -
ponse was also positively associated with increasing di -
sease duration (Table II). DAS28-3V-ESR remission was
also less probable in females and it was negatively asso-
ciated with higher ESR at baseline (Table III). A mo -
derate or good EULAR response and a HAQ res ponse
were also less probable in females (Table IV and V).
At 6 months, a good EULAR response was inverse-
ly associated with both female gender and higher ten-
der joint count at baseline (Table II). DAS28-3V-ESR re-
mission was less probable in females and it was
negatively associated with higher DAS28-3V-ESR at
baseline (Table III). A moderate or good EULAR res -
ponse was only positively associated with methotrexa -
te intake (Table IV). HAQ response was also less pro -
bable in females (Table V).
dIscussIon
Our results identified female gender as a consistent pre-
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
58
Predictors of resPonse to tnf blockers in Patients with Polyarticular Psoriatic arthritis
tAble I. bAselIne deMogrAPhIc, clInIcAl chArActerIstIcs of the study PoPulAtIon And resPonse
MeAsures At 3 And 6 Months 
Total
Demographic variables
Female, n (%) 180 98 (54.4)
Age, mean (S.D.), years 180 52.3 (12.1)
Educational level, mean (S.D.), years 114 8.3 (4.8)
No smoking, n (%) 130 93 (71.5)
No alcohol use, n (%) 125 89 (71.2)
BMI, mean (S.D.) 62 27.6 (5.4)
Disease characteristics
Presence of HLA-B27, n (%) 61 9 (14.8)
Presence of rheumatoid factor, n (%) 71 3 (4.2)
Presence of anti-CCP, n (%) 50 1 (2.0)
Extra-articular manifestations, n (%)* 180 61 (33.9)
Methotrexate use, n (%) 152 102 (67.1)
Disease duration, mean (S.D.) years 153 11.9 (9.9)
Disease activity at baseline
Swollen joints (28-count), mean (S.D.) 123 6.2 (4.2)
Tender joints (28-count), mean (S.D.) 123 9.3 (6.7)
PGA (VAS-scale), mean (S.D.) 126 64.4 (22.2)
ESR mm/h, mean (S.D.) 137 37.3 (28.4)
CRP mg/dl, mean (S.D) 130 2.8 (4.8)
DAS28-3V-ESR, mean (S.D.) 119 5.1 (1.3)
HAQ, mean (S.D.) 104 1.2 (0.7)
First TNF inhibitor, n (%) 180
Infliximab 27 (15.0)
Etanercept 81 (45.0)
Adalimumab 45 (25.0)
Golimumab 27 (15.0)
Response measures at 3 months, n (%)
Good EULAR response 86 38 (44.2)
DAS28 remission 107 34 (31.8)
Moderate or good EULAR response 86 72 (83.7)
HAQ response 65 51 (78.5)
Response measures at 6 months, nº (%)
Good EULAR response 90 52 (57.8)
DAS28 remission 130 64 (49.2)
Moderate or good EULAR response 90 78 (86.7)
HAQ response 87 72 (82.8)
n – Number; S.D. – Standard deviation; VAS-scale – Visual Analogic Scale; ESR – Erythrocyte Sedimentation Rate; CRP – C Reactive Protein;
DAS28-3V-ESR – Disease Activity Score 28, 3-variables; HAQ – Health Assessment Questionnaire; TNF – Tumour Necrosis Factor; EULAR –
European League Against Rheumatism. *Extra-articular manifestations including anterior uveitis, psoriasis, Crohn disease, ulcerative colitis,
unspecified colitis, aortitis, enthesitis, dactylitis, atrioventricular block, pericarditis, myocarditis, pulmonary fibrosis, IgA nephropathy,
secondary amyloidosis, cauda equine syndrome and other manifestations.
dictor of worse response to the first TNF blocker, in
PsA patients with polyarticular disease. Other less ro-
bust predictors of good response were longer disease
duration until the first biologic, concomitant therapy
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vious studies were: 1) response, defined by the achieve-
ment of remission or low disease activity status, and 2)
toxicity and efficacy, as assessed by survival on the
medi cation.(9) We aimed to evaluate predictors of res -
with MTX and lower disease activity at baseline, as in-
dicated by lower ESR, TJC and DAS28 3V-ESR.
The two most common outcomes used to assess pre-
dictors of effectiveness of TNF blocker therapy in pre-
tAble II. bAselIne PredIctIve fActors of good eulAr resPonse At 3 And 6 Months usIng unIvArIAble
And MultIvArIAble logIstIc regressIon AnAlysIs 
Good EULAR response at 3 months Good EULAR response at 6 months
Univariable logistic Multivariable logistic Univariable logistic Multivariable 
regression regression regression logistic regression
OR (CI 95%), OR (CI 95%), OR (CI 95%), OR (CI 95%),
p-value (n=51 to 86) p-value (n=75) p-value (n=55 to 90) p-value (n=42)
Gender (female) 0.154 (0.059,0.401), 0.082 (0.024,0.278), 0.091 (0.032,0.259), 0.060 (0.011,0.325), 
p<0.001 p<0.001 p<0.001 p=0.001
Age 1.006 (0.972,1.041), 0.985 (0.952,1.019), 
p=0.739 p=0.381
Disease duration 1.061 (1.009,1.116), 1.091 (1.026,1.159), 0.993 (0.948,1.040), 
until first biologic p=0.020 p=0.005 p=0.780
Educational level 1.015 (0.906,1.137), 1.101 (0.971,1.248), 
(years) p=0.797 p=0.133
Body mass index 0.974 (0.877,1.083), 0.875 (0.773,0.990), 
#
(kg/m2) p=0.633 p=0.034
Current smoking 0.640 (0.145,2.815), 2.500 (0.463,13.495), 
p=0.555 p=0.287
Current alcohol use 1.450 (0.440,4.778), 5.280 (1.058,26.346), 2.208 (0.309,15.777), 
p=0.541 p=0.042 p=0.430
Extra-articular 0.794 (0.327,1.924), 1.750 (0.702,4.360), 
manifestations p=0.609 p=0.230
Methotrexate use 1.400 (0.547,3.580), 1.733 (0.684,4.394), 
p=0.482 p=0.246
Swollen joints 0.929 (0.830,1.039), 0.927 (0.829,1.036), 
(28-count) p=0.199 p=0.182
Tender joints 0.960 (0.899,1.026), 0.894 (0.830,0.963), 0.892 (0.801,0.992), 
(28-count) p=0.229 p=0.003 p=0.036
PGA (VAS-scale) 0.988 (0.965,1.011), 0.977 (0.955,1.000), 
#
p=0.291 p=0.048
CRP (mg/dl) 0.982 (0.902,1.070), 0.871 (0.722,1.052), 
p=0.684 p=0.151
ESR (mm/h) 0.984 (0.968,1.000), 0.988 (0.974,1.002), 
p=0.055 p=0.105
DAS28-3V-ESR 0.789 (0.555,1.122), 0.701 (0.490,1.004), 
p=0.187 p=0.052
HAQ 0.451 (0.191,1.064), 0.534 (0.243,1.173), 
p=0.069 p=0.118
VAS-scale – Visual Analogic Scale; CRP – C Reactive Protein; DAS28-3V-ESR - Disease Activity Score 28, 3-variables; ESR – Erythrocyte
Sedimentation Rate; HAQ – Health Assessment Questionnaire; EULAR - European League Against Rheumatism; OR – Odds Ratio; 
# – not selected during multivariable logistic regression analysis.
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ponse, using multiple definitions, namely the EULAR
response and DAS28-3V-ESR remission criteria, both
previously validated in PsA. HAQ response was also
analyzed, as this measure of disability has also been
validated for patients with PsA16.
Female gender was a consistent predictive factor of
poor response to TNF blockers, as found by Glintborg
et al., who analyzed results from 764 patients with PsA
receiving TNF blocker therapy, from the nationwide
Danish DANBIO registry17. In a multiple logistic re-
tAble III. bAselIne PredIctIve fActors of dAs28 reMIssIon At 3 And 6 Months usIng unIvArIAble 
And MultIvArIAble logIstIc regressIon AnAlysIs 
DAS28 remission at 3 months DAS28 remission at 6 months
Univariable logistic Multivariable logistic Univariable logistic Multivariable logistic 
regression regression regression regression
OR (CI 95%), OR (CI 95%), OR (CI 95%), OR (CI 95%), 
p-value (n=62 to 107) p-value (n=58) p-value (n=74 to 130) p-value (n=63)
Gender (female) 0.093 (0.036,0.241), 0.083 (0.017,0.416), 0.115 (0.052,0.254), 0.060 (0.012,0.297), 
p<0.001 p=0.002 p<0.001 p=0.001
Age 0.971 (0.939,1.005), 0.959 (0.929,0.989), 
#
p=0.091 p=0.008
Disease duration 1.012 (0.968,1.058), 0.978 (0.941,1.016), 
until first biologic p=0.590 p=0.256
Educational level 1.056 (0.953,1.170), 1.033 (0.942,1.133), 
(years) p=0.300 p=0.492
Body mass index 0.880 (0.771,1.004), 0.934 (0.847,1.030), 
(kg/m2) p=0.056 p=0.171
Current smoking 0.436 (0.088,2.161), 1.000 (0.297,3.365), 
p=0.310 p=1.000
Current alcohol use 1.765 (0.545,5.709), 1.810 (0.629,5.203), 
p=0.343 p=0.271
Extra-articular 1.047 (0.446,2.459), 1.290 (0.620,2.684), 
manifestations p=0.916 p=0.495
Methotrexate use 0.868 (0.353,2.136), 1.423 (0.632,3.206), 
p=0.758 p=0.395
Swollen joints 0.828 (0.719,0.952), 
#
0.830 (0.730,0.944), 
#
(28-count) p=0.008 p=0.005
Tender joints 0.843 (0.762,0.933), 
#
0.874 (0.805,0.948), 1.060 (0.879,1.277), 
(28-count) p=0.001 p=0.001 p=0.542
PGA (VAS-scale) 0.972 (0.950,0.995), 
#
0.990 (0.971,1.010), 
p=0.016 p=0.332
CRP (mg/dl) 0.838 (0.668,1.051), 0.758 (0.607,0.946), 0.959 (0.713,1.291), 
p=0.127 p=0.014 p=0.784
ESR (mm/h) 0.938 (0.908,0.969), 0.935 (0.891,0.982), 0.967 (0.949,0.985), 
#
p<0.001 p=0.007 p<0.001
DAS28-3V-ESR 0.297 (0.167,0.527), 
#
0.401 (0.521,0.640), 0.344 (0.133,0.893), 
p<0.001 p<0.001 p=0.028
HAQ 0.119 (0.400,0.360), 0.613 (0.140,2.694), 0.388 (0.183,0.821), 2.401 (0.585,9.856), 
p<0.001 p=0.517 p=0.013 p=0.224
VAS-scale – Visual Analogic Scale; CRP – C Reactive Protein; DAS28-3V-ESR - Disease Activity Score 28, 3-variables; ESR – Erythrocyte
Sedimentation Rate; HAQ – Health Assessment Questionnaire; EULAR - European League Against Rheumatism; OR – Odds Ratio; 
# – not selected during multivariable logistic regression analysis
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gression analysis using EULAR good response as the
dependent variable, female gender was associated with
a less probable EULAR good clinical response. Saad A.
et al. included 596 PsA patients of the British Society
for Rheumatology Biologics Register (BSRBR) and
found that, for the EULAR response at 6 months, both
univariable and multivariable analyses suggested that
being female resulted in lower response rates (OR 0.51,
tAble Iv. bAselIne PredIctIve fActors of ModerAte or good eulAr resPonse At 3 And 6 Months
usIng unIvArIAble And MultIvArIAble logIstIc regressIon AnAlysIs
Moderate or good EULAR response Moderate or good EULAR response 
at 3 months at 6 months
Univariable logistic Multivariable logistic Univariable logistic Multivariable logistic 
regression regression regression regression
OR (CI 95%), OR (CI 95%), OR (CI 95%), OR (CI 95%), 
p-value (n = 51 to 86) p-value (n = 38) p-value (n = 55 to 90) p-value (n = 90)
Gender (female) 0.091 (0.011,0.091), 0.091 (0.011,0.091), 0.351 (0.088,1.395), 
p=0.024 p=0.024 p=0.137
Age 1.010 (0.966,1.057), 1.014 (0.968,1.063), 
p=0.656 p=0.548
Disease duration 1.006 (0.946,1.070), 1.002 (0.936,1.074), 
until first biologic p=0.851 p=0.947
Educational level 1.012 (0.869,1.178), 0.915 (0.760,1.102), 
(years) p=0.878 p=0.349
Body mass index 0.874 (0.765,0.998), 
#
0.934 (0.803,1.085), 
(kg/m2) p=0.046 p=0.371
Current smoking 0.375 (0.079,1.781), 0.549 (0.053,5.639), 
p=0.217 p=0.614
Current alcohol 1.350 (0.256,7.117), 1.067 (0.109,10.449), 
use p=0.723 p=0.956
Extra-articular 0.754 (0.236,2.410), 1.588 (0.397,6.360), 
manifestations p=0.633 p=0.513
Methotrexate use 1.349 (0.404,4.504), 4.667 (1.320,16.497), 4.667 (1.320,16.497), 
p=0.626 p=0.017 p=0.017
Swollen joints 1.160 (0.968,1.390), 1.263 (1.006,1.585), 
#
(28-count) p=0.109 p=0.045
Tender joints 1.009 (0.925,1.100), 0.971 (0.887,1.064), 
(28-count) p=0.847 p=0.529
PGA (VAS-scale) 0.972 (0.940,1.004), 1.000 (0.971,1.030), 
p=0.090 p=0.992
CRP (mg/dl) 1.074 (0.872,1.323), 0.995 (0.893,1.108), 
p=0.503 p=0.924
ESR (mm/h) 0.990 (0.972,1.007), 0.990 (0.972,1.008), 
p=0.251 p=0.272
DAS28-3V-ESR 1.080 (0.982,1.712), 1.102 (0.679,1.789), 
p=0.742 p=0.693
HAQ 0.253 (0.070,0.919), 
#
2.395 (0.739,7.761), 
p=0.037 p=0.145
VAS-scale – Visual Analogic Scale; CRP – C Reactive Protein; DAS28-3V-ESR - Disease Activity Score 28, 3-variables; ESR – Erythrocyte
Sedimentation Rate; HAQ – Health Assessment Questionnaire; EULAR – European League Against Rheumatism; OR – Odds Ratio; 
# – not selected during multivariable logistic regression analysis.
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tAble v. bAselIne PredIctIve fActors of hAQ resPonse At 3 And 6 Months usIng unIvArIAble 
And MultIvArIAble logIstIc regressIon AnAlysIs
HAQ response at 3 months HAQ response at 6 months
Univariable logistic Multivariable logistic Univariable logistic Multivariable logistic 
regression regression regression regression
OR (CI 95%), OR (CI 95%), OR (CI 95%), OR (CI 95%), 
p-value (n = 36 to 65) p-value (n = 65) p-value (n = 58 to 87) p-value (n = 87)
Gender (female) 0.074 (0.009,0.608), 0.074 (0.009,0.608), 0.138 (0.029,0.654), 0.138 (0.029,0.654), 
p=0.015 p=0.015 p=0.013 p=0.013
Age 0.962 (0911,1.015), 0.998 (0954,1.044), 
p=0.158 p=0.936
Disease duration 1.025 (0.950,1.106), 0.998 (0.945,1.054), 
until first biologic p=0.525 p=0.937
Educational level 0.938 (0.805,1.094), 0.964 (0.838,1.109), 
(years) p=0.415 p=0.609
Body mass index 1.160 (0.793,1.696), 1.126 (0.884,1.434), 
(kg/m2) p=0.445 p=0.335
Current smoking 0.857 (0.149,4.922), 1.680 (0.188,14.981), 
p=0.863 p=0.642
Extra-articular 1.613 (0.445,5.851), 1.650 (0.478,5.701), 
manifestations p=0.467 p=0.429
Methotrexate use 1.057 (0.285,3.928), 1.469 (0.436,4.946), 
p=0.934 p=0.535
Swollen joints 0.942 (0.810,1.095), 0.962 (0.817,1.133), 
(28-count) p=0.437 p=0.646
Tender joints 0.923 (0.842,1.012), 0.950 (0.871,1.036), 
(28-count) p=0.087 p=0.246
PGA (VAS-scale) 0.983 (0.956,1.012), 1.012 (0.986,1.039), 
p=0.248 p=0.377
CRP (mg/dl) 1.372 (0.899,2.095), 0.962 (0.782,1.183), 
p=0.143 p=0.714
ESR (mm/h) 1.003 (0.983,1.024), 0.999 (0980,1.018), 
p=0.762 p=0.914
DAS28-3V-ESR 0.742 (0.457,1.205), 0.730 (0.448,1.189), 
p=0.227 p=0.206
HAQ 0.712 (0.271,1.869), 1.174 (0.521,2.644), 
p=0.490 p=0.699
VAS-scale – Visual Analogic Scale; CRP – C Reactive Protein; DAS28-3V-ESR - Disease Activity Score 28, 3-variables; ESR – Erythrocyte
Sedimentation Rate; HAQ – Health Assessment Questionnaire; EULAR - European League Against Rheumatism; OR – Odds Ratio; 
# – not selected during multivariable logistic regression analysis
95% CI 0.34, 0.78). In the same study, regarding
DAS28 remission, females were also less likely to
achieve disease remission, in both univariable and mul-
tivariable models (adjusted OR 0.34, 95% CI 0.21,
0.57)18. Saber et al. studied a total of 152 PsA patients
and found that an increased DAS28 response was in-
dependently associated with male gender and patient-
-derived indices including HAQ, patient global VAS
and early morning stiffness. However, linear regression
analysis of baseline characteristics suggested that HAQ
at baseline was the sole predictor of DAS28 at one year,
not sustaining the effect of gender on the response to
TNF blockers in this analysis19. The influence of gen-
der was also observed with other outcomes measures,
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namely drug survival. Glintborg et al. included baseline
disease parameters and patient characteristics in a Cox
regression analysis for TNF blockers drug survival. Fe-
male gender was associated with shorter TNF blocker
drug survival [Hazard Ratio (HR) 1.42, 95% CI 1.11,
1.80] 17.
A HAQ response was also less probable in females,
in our study. The association between female gender
and HAQ scores had already been suggested in other
studies. Husted et al. assessed predictors of physical
functioning over the course of PsA, by investigating
transitions between predefined states of the HAQ, and
reported that female gender predicted faster decline in
disability20. Tillett et al. reported that female gender
predicted worse HAQ scores after 10 years from the
onset of PsA21. However, this was the first study show-
ing differences on HAQ response to TNF blockers as-
sociated with gender of PsA patients.
A similar effect of female gender as a predictive fac-
tor of poor response to TNF blockers had already been
described in ankylosing spondylitis and rheumatoid
arthritis22. The reasons remain unknown, however,
seve ral hypotheses such as sex hormones and muscu-
loskeletal performance have been proposed. A rela-
tionship between higher testosterone levels and the
presence of HLA-B27 have been reported in spondy-
loarthritis and this characteristic could play a role on
disease activity. However, the mechanism which could
be responsible for a better response to TNF blockers in
those patients remains unknown23, 24. Another possible
contributing factor may be related to the higher preva-
lence of concomitant generalized pain syndrome/fi-
bromyalgia in the female gender25. This could be an im-
portant contributing factor as fibromyalgia-associated
pain and fatigue are significantly more frequent in pa-
tients with PsA compared to controls26.
We found that a moderate or good EULAR response
at 6 months was more probable in patients using
methotrexate at baseline. Glintborg et al. included base-
line disease parameters and patient characteristics in a
Cox regression analysis for TNF blocker drug survival.
The lack of concomitant MTX use was associated with
worse results with this surrogate outcome measure (HR
1.37, 95% CI 1.07, 1.75)17. Kristensen et al. studied
261 patients with active PsA, starting TNF blocker
thera py for the first time in southern Sweden (from the
South Swedish Arthritis Treatment Group register).
Concomitant MTX (HR 0.64, 95% CI 0.39-0.95),
etaner cept and CRP levels at treatment initiation were
associated with better overall drug survival. The im-
proved drug survival with concomitant MTX appeared
to be related to significantly fewer dropouts because of
adverse events (HR 0.24, 95% CI 0.11, 0.52)27. In
summa ry, the use of MTX had already been shown to
be associated with TNF blocker drug survival; how -
ever this is the first time that an association with a bet-
ter clinical response is reported. The underlying me -
chanism for this association is unknown. One of the
hypotheses for this observation could be the prevention
of development of autoantibodies to TNF blockers –
however this hypothesis remains controversial and un-
proven. On the other hand, a recent meta-analysis did
not show any statistical difference between monothera -
py and concomitant use of MTX when analyzing
ACR20, ACR50 and ACR70 as response measures28. It
seems that this mechanism could play an important
role on the immunogenicity; however, his influence is
more established in rheumatoid arthritis than in PsA.
In some of the outcomes analyzed in our study, we
also found better responses in patients with longer
disea se duration until first biologic and lower disease
activity at baseline, as indicated by lower ESR, TJC and
DAS28 3V-ESR. These observations could be explained
by the difficulty to induce remission in PsA patients
with highly active disease. They could also be spurious
associations and previous literature has shown con-
flicting results.
Several other predictors of response were proposed
to explain TNF blockers outcomes in PsA patients.
However, Maneiro et al., in a recent meta-analysis,
found some predictors of response to TNF blockers in
AS, but no robust predictors of response in PsA were
identified. Despite of several studies suggesting poo rer
response in women, this association was not confirmed
in this meta-analysis28.
The most important limitation of our study is the
missing data that led to exclusion of a large number of
patients treated with TNF blockers in the Reuma.pt
registry. This may have resulted in selection bias and/or
loss of power to detect some associations. Another limi -
tation is related to the missing data regarding all varia -
bles included in the CASPAR classification criteria,
which forced the investigators to use solely the dia -
gnosis of PsA made by the rheumatologist. This limi-
tation may be attenuated given that the diagnosis by
the rheumatologist is often the gold-standard in classi-
fication criteria studies. It is important to acknowledge
that the outcomes used were primarily made to evalua -
te rheumatoid arthritis (albeit being validated in PsA)
and that they can be less precise in PsA. One of the
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strengths of our study is the large number of response
outcomes that were analyzed and the real-life setting of
Reuma.pt.
In conclusion, we found that gender was the most
consistent predictor of response to the first anti-TNF
therapy, across different response measures, in patients
with polyarticular PsA, with males having a higher
probability of response than females. These findings
suggest that gender-related biochemical, hormonal and
psychological factors could play an important role on
the response to anti-TNF therapy in PsA.
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